FIELD: biotechnology.
SUBSTANCE: what is presented is conjugate aimed at CD26, including anti-CD26 antibody connected with triptolide. Novel antibody-drug conjugate is produced by conjugation of anti-CD26 antibody (YS110) with triptolide and is a highly effective inhibitor of CD26-positive malignant mesothelioma cells.
EFFECT: invention can be used for effective chemotherapy of malignant mesothelioma with reduced side effects on the patient.
7 cl, 54 dwg, 5 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMHRII BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCERS | 2018 |
|
RU2797506C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| HUMANIZED ANTI-PSMA ANTIBODIES | 2019 |
|
RU2794450C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| ANTI-BAG2 ANTIBODY AND METHODS OF TREATING CANCER | 2020 |
|
RU2815586C2 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
